Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers

Table 4 Intraindividual correlations of the treatment related change after empagliflozin or dapagliflozin treatment in comparison to baseline

	Glycated hemoglobin		Fasting plasma glucose		Body mass index		Systolic blood pressure
	r	p-value	r	p-value	r	p-value	r	p-value
Empagliflozin
Homoarginine	0.041	0.736	0.005	0.969	− 0.079	0.513	0.037	0.758
Arginine	− 0.204	0.088	− 0.116	0.336	− 0.081	0.502	0.044	0.715
ADMA	− 0.171	0.153	− 0.010	0.931	− 0.142	0.236	− 0.134	0.266
SDMA	− 0.175	0.144	− 0.042	0.725	− 0.007	0.952	− 0.279	0.019
Dapagliflozin
Homoarginine	− 0.104	0.432	− 0.210	0.110	0.020	0.882	0.278	0.033
Arginine	− 0.186	0.159	− 0.195	0.139	− 0.066	0.619	0.366	0.004
ADMA	− 0.110	0.407	− 0.182	0.168	− 0.127	0.337	0.073	0.581
SDMA	− 0.075	0.571	− 0.259	0.048	0.012	0.928	− 0.073	0.583

ISSN: 1475-2840